Sugi Predict

Sugi Predict / Compounds / SCHEMBL3367772

SCHEMBL3367772

SCHEMBL3367772

O=S(=O)(ON=C(c1ccccc1)C(F)(F)F)c1ccc(O)cc1

nearest known ligand 0.42

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 3/20 0.42
▸ MAPT P10636 4/20 0.42
▸ KMT2A Q03164 2/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ MEN1 O00255 1/20 0.37
▸ ESR1 P03372 2/20 0.36
▸ PTGS2 P35354 2/20 0.35
▸ LMNA P02545 1/20 0.35
▸ CES2 O00748 1/20 0.35
▸ CES1 P23141 1/20 0.35
▸ GAA P10253 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16063707 0.87 LMNA (0.42) KDM4EMAPTKMT2AALDH1A1MEN1
SCHEMBL14472762 0.86 KMT2A (0.39) KDM4EMAPTKMT2AALDH1A1MEN1
SCHEMBL383221 0.85 GAA (0.44) KDM4EMAPTKMT2AALDH1A1PTGS2
SCHEMBL546375 0.85 GAA (0.44) KDM4EMAPTKMT2AALDH1A1PTGS2
SCHEMBL384443 0.82 MAPT (0.54) KDM4EMAPTALDH1A1LMNA
SCHEMBL545473 0.82 MAPT (0.54) KDM4EMAPTALDH1A1LMNA
SCHEMBL547034 0.82 MAPT (0.44) KDM4EMAPTKMT2AALDH1A1MEN1
SCHEMBL547035 0.82 MAPT (0.44) KDM4EMAPTKMT2AALDH1A1MEN1
SCHEMBL546361 0.82 TDP1 (0.45) KDM4EMAPTKMT2AALDH1A1MEN1
SCHEMBL546362 0.82 TDP1 (0.45) KDM4EMAPTKMT2AALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1595182-B1 HALOGENATED OXIME DERIVATIVES AND THE USE THEREOF AS LATENT ACIDS BASF SE (DE) 2015-09-30 — — EP disclosed
US-8241822-B2 Halogenated oxime derivatives and the use therof as latent acids BASF SE (DE) 2012-08-14 — — US disclosed
US-7687220-B2 Oxime derivatives and use thereof as latent acids CIBA SPECIALTY CHEMICALS CORPORATION (US) 2010-03-30 — — US disclosed
EP-1320785-B1 OXIME DERIVATIVES AND THE USE THEREOF AS LATENT ACIDS BASF SE (DE) 2010-02-17 — — EP disclosed
US-20090042114-A1 Halogenated oxime derivatives and the use therof as latent acids YAMATO HITOSHI 2009-02-12 — — US disclosed
US-7399577-B2 Halogenated oxime derivatives and the use thereof CIBA SPECIALTY CHEMICALS CORPORATION (US) 2008-07-15 — — US disclosed
US-20080085458-A1 Oxime Derivatives And Use Thereof As Latent Acids CIBA SPECIALTY CHEMICALS CORPORATION 2008-04-10 — — US disclosed
US-7244544-B2 Oxime derivatives and the use thereof as latent acids CIBA SPECIALTY CHEMICALS CORPORATION (US) 2007-07-17 — — US disclosed
EP-1769286-A2 OXIME DERIVATIVES AND THE USE THEROF AS LATENT ACIDS Ciba Specialty Chemicals Holding Inc. (CH) 2007-04-04 — — EP disclosed
US-20060246377-A1 Halogenated oxime derivatives and the use thereof as latent acids BASF SE (DE) 2006-11-02 — — US disclosed
US-6986981-B2 Oxime derivatives and the use thereof as latent acids CIBA SPECIALTY CHEMICALS CORPORATION (US) 2006-01-17 — — US disclosed
EP-1392675-B1 SUBSTITUTED OXIME DERIVATIVES AND THE USE THEREOF AS LATENT ACIDS CIBA SC HOLDING AG (CH) 2005-02-09 — — EP disclosed
US-20040209186-A1 Substituted oxime derivatives and the use thereof as latent acids CIBA SPECIALTY CHEMICALS CORP. 2004-10-21 — — US disclosed
EP-1392675-A1 SUBSTITUTED OXIME DERIVATIVES AND THE USE THEREOF AS LATENT ACIDS Ciba SC Holding AG (CH) 2004-03-03 — — EP disclosed
US-20040002007-A1 Oxime derivatives and the use thereof as latent acids CIBA SPECIALTY CHEMICALS CORP. 2004-01-01 — — US disclosed
EP-1320785-A2 OXIME DERIVATIVES AND THE USE THEREOF AS LATENT ACIDS Ciba SC Holding AG (CH) 2003-06-25 — — EP disclosed
US-6512020-B1 Photosensitive acid-donors in chemically amplified resist formulations. activated by irradiation with actinic electromagnetic radiation and electron beams. CIBA SPECIALTY CHEMICALS CORPORATION 2003-01-28 — — US disclosed
WO-2002098870-A1 SUBSTITUTED OXIME DERIVATIVES AND THE USE THEREOF AS LATENT ACIDS CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 2002-12-12 — — WO disclosed
WO-2002025376-A2 OXIME DERIVATIVES AND THE USE THEREOF AS LATENT ACIDS CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 2002-03-28 — — WO disclosed
US-6261738-B1 LATENT CURING CATALYSTS FOR PHOTORESISTS SUCH AS 2,2,2-TRIFLUORO-1-PHENYL-ETHANONE OXIME-O-METHYL SULFONATE CIBA SPECIALTY CHEMICALS CORPORATION 2001-07-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042114-A1 Halogenated oxime derivatives and the use therof as latent acids AHR, CCNT1, RTF1 KDM4E 4254/4885MAPT 3976/4885KMT2A 1461/4885
US-20060246377-A1 Halogenated oxime derivatives and the use thereof as latent acids AHR, ARSA, SULT1A1 KDM4E 2197/4885MAPT 4298/4885KMT2A 688/4885
US-20080085458-A1 Oxime Derivatives And Use Thereof As Latent Acids ARSA, CYP2S1, QSOX1 KDM4E 2443/4885MAPT 4824/4885KMT2A 2316/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.